Jun 09, 2019
A Single Course of Provention's PRV-031 (Teplizumab) Delays Type 1 Diabetes Onset in High-Risk Individuals by at Least Two Years
May 08, 2019
Provention Bio Reports First Quarter 2019 Financial Results
May 08, 2019
Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis
Apr 24, 2019
Provention Bio Completes Enrollment of Phase 2a PRINCE Clinical Trial with PRV-6527 in Patients with Moderate to Severe Crohn's Disease
Apr 09, 2019
Provention Bio Initiates Phase 3 PROTECT Clinical Trial with PRV-031 (Teplizumab) in Patients with Recent Onset Type 1 Diabetes
Apr 02, 2019
Provention Bio Announces Key Additions to its Senior Management Team
Mar 28, 2019
Provention Bio Appoints Jeffrey Bluestone, PhD, to Board of Directors
Mar 19, 2019
Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
Feb 13, 2019
Provention Bio To Present at 8th Annual Leerink Partners Global Healthcare Conference
Jan 28, 2019
Provention Bio Receives Notice of Allowance from United States Patent and Trademark Office for Patent on Multi-Strain Coxsackievirus B Vaccine for Preventing or Treating Type 1 Diabetes (T1D)
Jan 03, 2019
Provention Bio Announces Publication in "Expert Review of Vaccines" Describing the Scientific Rationale for Developing a Vaccine for Type 1 Diabetes by Targeting Coxsackievirus B
Nov 28, 2018
Provention Bio Joins the C-Path Type 1 Diabetes (T1D) Consortium
Nov 01, 2018
Provention Bio to Report Third Quarter 2018 Financial Results and Host Conference Call on Thursday, November 8, 2018
Oct 23, 2018
Provention Bio Announces Completion of Enrollment of Phase 1b Clinical Trial of PRV-300 in Moderate-to-Severe Ulcerative Colitis
Sep 05, 2018
Provention Bio Appoints Accomplished Biotech Executive, Chip Catlin, to its Board of Directors
Aug 13, 2018
Provention Bio Reports Second Quarter 2018 Financial Results and Provides Business Update
Jul 31, 2018
Provention Bio Appoints Leading T1D Expert, Dr. Mark Rigby, as Vice President, Clinical Development
May 09, 2018
Provention Bio Announces Agreements with MacroGenics for Two Clinical-Stage Assets for the Treatment of Autoimmune Disorders
May 07, 2018
Provention Bio Selects Intravacc as Product Development and Manufacturing Partner for Coxsackievirus B Vaccine
Sep 28, 2017
Provention Bio, Inc. Completes its Executive Management Team